The following are the decisions for drugs that have been considered by the drug advisory committee for inclusion to the WSIB formularies:
- Aripiprazole (PDF)
- Benzodiazepines (PDF)
- Botulinum Toxin A: Botox®,Botox Cosmetic®, Xeomin®
- Buprenorphine (Opioid use disorder)
- Buprenorphine (Treatment of chronic pain) (PDF)
- Cannabinoid: Nabilone (PDF)
- Compounded Topical Analgesics (PDF)
- Corticosteroid injections (musculoskeletal conditions)*
- Desvenlafaxine (PDF)
- Diclofenac Sodium Solution 1.5% (PDF)
- Duloxetine (PDF)
- Escitalopram (PDF)
- HIV Post-Exposure Prophylaxis (PDF)
- Hypnotics: Zopiclone, Trazodone and Tryptophan (PDF)
- Oxycodone/Naloxone Controlled Release (PDF)
- Paliperidone (PDF)
- Piroxicam (PDF)
- Pregabalin (PDF)
- Skeletal Muscle Relaxants (PDF)
- Tapentadol Controlled Release (PDF)
- Tramadol (PDF)
- Viscosupplements (PDF)
- Ziprasidone (PDF)